Clinical Trial Update: A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy

View source ↗

Summary

This completed real-world clinical trial evaluates outcomes of disease-modifying therapy for patients with spinal muscular atrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Muscular Atrophy, Spinal | Status: COMPLETED